ISN-ASON Webinar: Diagnosing and Managing Immune Checkpoint Inhibitor Nephrotoxicity and GFR Assessment: Insights from ASON Position Statements

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but pose unique challenges for nephrologists due to their potential nephrotoxic effects. This ISN webinar will explore real-world case presentations on ICI-related kidney injury, drawing upon the latest guidance from the American Society of Onconephrology (ASON) position statement. The session will also address glomerular filtration rate (GFR) assessment and its implications for drug dosing and pseudo-acute kidney injury (AKI), using a second illustrative case and insights from the corresponding ASON statement.

Attendees will gain practical tools to recognize and manage ICI-associated nephrotoxicity and improve clinical decision-making regarding kidney function estimation and treatment optimization.

Learning objectives:

- Describe the pathophysiology and diagnostic approach to immune checkpoint inhibitor-related nephrotoxicity.
- Summarize key recommendations from the ASON position statements on ICI nephrotoxicity and GFR assessment.
- Apply evidence-based strategies for drug dosing and differentiation between true and pseudo-AKI using GFR estimations.
- Analyze complex clinical cases to inform best practices in nephrology care involving oncology and pharmacologic interactions.

Further reading:

• Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology
• Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology
• Performance of Creatinine and Cystatin-Based Equations on Estimating Measured GFR in People with Hematological and Solid Cancers